Compare AbbVie Inc (ABBV) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? AbbVie Inc trades at $253.79 (market cap $449.91B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.53. The key difference: AbbVie Inc pays a 2.72% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ABBV | YMAG | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $261.07 | $15.98 |
52-Week Low | $184.85 | $11.00 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
YMAG trades at $11.70, up 2.01% today, but technical indicators signal bearish momentum with resistance at $12. The ETF maintains weekly dividend distributions, though recent analysis highlights concerns about NAV decay from its synthetic covered call strategy on Magnificent Seven stocks. Mixed sentiment prevails with some analysts seeing tactical opportunities in rangebound markets while others cite limited upside potential.
Outlook remains cautious due to structural NAV erosion risks and high expense ratios. The fund's performance depends heavily on volatility monetization from its underlying option strategy, creating both income opportunities and capital depreciation risks in trending markets. Investors should weigh the high yield against potential long-term underperformance versus the broader market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
